ASHEVILLE, N.C.--(BUSINESS WIRE)--Announcing a fistful of Foundation $200,000 research grants, a small patient advocacy group has formed MPN Genetics (mGEN) to help bring new gene editing technologies to a rare blood cancer. mGEN is supported by an elite international group of blood cancer scientists and specialists.
“Our strategy,” says mGEN Team Leader Zhenya Senyak, a myelofibrosis patient, “is simple. We want to help research biologists and genomic scientists focus on myeloproliferative neoplasms (MPNs) by opening access to research funding and supporting collaboration with hematologists and other clinicians. Right now, hematologists are new to gene editing and genetic engineering scientists likely never heard of MPNs.“
Help employers find you! Check out all the jobs and post your resume.
